NCT06603246View on ClinicalTrials.gov

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions
Non Cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary Disease
Interventions
DRUG

GDC-6988

GDC-6988 will be administered using a dry powder inhalation

Trial Locations (7)

27514

RECRUITING

University of North Carolina Clinical Research Center, Chapel Hill

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

78006

COMPLETED

TTS Research, Boerne

94304

RECRUITING

Stanford Center for Excellence in Pulmonary Biology, Palo Alto

35216-1927

WITHDRAWN

Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills

66160 8500

RECRUITING

University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd, Kansas City

15213 3236

RECRUITING

UPMC Montefiore Hospital, Pittsburgh

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY